{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:16:34Z","timestamp":1781050594541,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T00:00:00Z","timestamp":1591660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Japanese Association of Medical Sciences","award":["150-2019-3-05"],"award-info":[{"award-number":["150-2019-3-05"]}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K16741"],"award-info":[{"award-number":["JP20K16741"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abdominal\/pelvic lymph node (LN) oligometastasis, a pattern of treatment failure, is observed occasionally, and radiotherapy may work as salvage therapy. The optimal prescription dose, however, is yet to be determined. This study assessed the efficacy of high-dose radiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The medical records of 113 patients at 4 institutes were retrospectively analysed who had 1 to 5 abdominal\/pelvic LN oligometastases and were treated with definitive radiotherapy between 2008 and 2018. The exclusion criteria included non-epithelial tumours, uncontrolled primary lesions, palliative intent, and re-irradiation. The prescription dose was evaluated by using the equivalent dose in 2\u2009Gy fractions (EQD2). Patients receiving EQD2\u2009\u2265\u200960\u2009Gy were placed into the high-dose group, and the remaining others the low-dose group. Kaplan-Meier analyses were performed to evaluate overall survival (OS), local control (LC), and progression-free survival (PFS). Univariate log-rank and multivariate Cox proportional hazards model analyses were performed to explore predictive factors. Adverse events were compared between the high-dose and low-dose groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The primary tumour sites included the colorectum (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928), uterine cervix (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927), endometrium (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915), and ovaries (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910). The rate of 2-year OS was 63.1%, that of LC 59.7%, and that of PFS 19.4%. On multivariate analyses, OS were significantly associated with solitary oligometastasis (hazard ratio [HR]: 0.48,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02), LC with high-dose radiotherapy (HR: 0.93,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and PFS with long disease-free interval (HR: 0.59,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). Whereas high-dose radiotherapy did not significantly improve 2-year OS in the entire cohort (74.8% in the high-dose vs. 52.7% in the low-dose;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.08), it did in the subgroup of solitary oligometastasis (88.8% in the high-dose vs. 56.3% in the low-dose;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). As for Late grade\u2009\u2265\u20093 adverse event, ileus was observed in 7 patients (6%) and gastrointestinal bleeding in 4 (4%). No significant association between the irradiation dose and adverse event incidence was found.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>As salvage therapy, high-dose radiotherapy was recommendable for oligometastasis in the abdominal\/pelvic LNs. For solitary oligometastasis, LC and OS were significantly better in the high-dose group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07033-7","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T09:20:04Z","timestamp":1591694404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal\/pelvic lymph nodes: a retrospective study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-1594","authenticated-orcid":false,"given":"Makoto","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Mizumatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshie","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichirou","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"7033_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8\u201310.","journal-title":"J Clin Oncol"},{"key":"7033_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s12094-017-1665-7","volume":"19","author":"J Lee","year":"2017","unstructured":"Lee J, Yoon HI, Rha SY, Hyung WJ, Lee YC, Lim JS, Kim HS, Koom WS. Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer. Clin Transl Oncol. 2017;19:1268\u201375.","journal-title":"Clin Transl Oncol"},{"key":"7033_CR3","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1002\/hed.24909","volume":"39","author":"M Ito","year":"2017","unstructured":"Ito M, Kodaira T, Tachibana H, Tomita N, Makita C, Koide Y, Kato D, Abe T, Muro K, Tajika M, et al. Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. Head Neck. 2017;39:2406\u201315.","journal-title":"Head Neck"},{"key":"7033_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/COC.0b013e3182610878","volume":"37","author":"BA Jereczek-Fossa","year":"2014","unstructured":"Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R, Fossati Ing P, Gherardi F, Alterio D, Zerini D, et al. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol. 2014;37:227\u201333.","journal-title":"Am J Clin Oncol"},{"key":"7033_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1080\/07357907.2016.1197235","volume":"34","author":"C Franzese","year":"2016","unstructured":"Franzese C, Cozzi L, Franceschini D, D'Agostino G, Comito T, De Rose F, Navarria P, Mancosu P, Tomatis S, Fogliata A, Scorsetti M. Role of stereotactic body radiation therapy with volumetric-modulated arcs and high-intensity photon beams for the treatment of Abdomino-pelvic lymph-node metastases. Cancer Investig. 2016;34:348\u201354.","journal-title":"Cancer Investig"},{"key":"7033_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.rpor.2014.10.004","volume":"20","author":"BA Jereczek-Fossa","year":"2015","unstructured":"Jereczek-Fossa BA, Ronchi S, Orecchia R. Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Radiother. 2015;20:472\u201383.","journal-title":"Rep Pract Oncol Radiother"},{"key":"7033_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.clon.2017.11.010","volume":"30","author":"S Gandhidasan","year":"2018","unstructured":"Gandhidasan S, Ball D, Kron T, Bressel M, Shaw M, Chu J, Chander S, Wheeler G, Plumridge N, Chesson B, et al. Single fraction stereotactic ablative body radiotherapy for Oligometastasis: outcomes from 132 consecutive patients. Clin Oncol (R Coll Radiol). 2018;30:178\u201384.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"7033_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/1748-717X-7-164","volume":"7","author":"I Fumagalli","year":"2012","unstructured":"Fumagalli I, Bibault JE, Dewas S, Kramar A, Mirabel X, Prevost B, Lacornerie T, Jerraya H, Lartigau E. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol. 2012;7:164.","journal-title":"Radiat Oncol"},{"key":"7033_CR9","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051\u20138.","journal-title":"Lancet"},{"key":"7033_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"7033_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"7033_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"7033_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ijrobp.2010.05.032","volume":"81","author":"M Bignardi","year":"2011","unstructured":"Bignardi M, Navarria P, Mancosu P, Cozzi L, Fogliata A, Tozzi A, Castiglioni S, Carnaghi C, Tronconi MC, Santoro A, Scorsetti M. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. Int J Radiat Oncol Biol Phys. 2011;81:831\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7033_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/030089161309900207","volume":"99","author":"R Corvo","year":"2013","unstructured":"Corvo R, Lamanna G, Vagge S, Belgioia L, Bosetti D, Aloi D, Timon G, Bacigalupo A. Once-weekly stereotactic radiotherapy for patients with oligometastases: compliance and preliminary efficacy. Tumori. 2013;99:159\u201363.","journal-title":"Tumori"},{"key":"7033_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1748-717X-7-204","volume":"7","author":"F Alongi","year":"2012","unstructured":"Alongi F, Fogliata A, Clerici E, Navarria P, Tozzi A, Comito T, Ascolese AM, Clivio A, Lobefalo F, Reggiori G, et al. Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal\/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol. 2012;7:204.","journal-title":"Radiat Oncol"},{"key":"7033_CR16","doi-asserted-by":"publisher","first-page":"261096","DOI":"10.1155\/2012\/261096","volume":"2012","author":"Y Niibe","year":"2012","unstructured":"Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med. 2012;2012:261096.","journal-title":"Pulm Med"},{"key":"7033_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12894-019-0515-z","volume":"19","author":"C Oehler","year":"2019","unstructured":"Oehler C, Zimmermann M, Adam L, Curschmann J, Sumila M, Strebel RT, Cathomas R, Li Q, Schneider U, Zwahlen DR. Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience. BMC Urol. 2019;19:84.","journal-title":"BMC Urol"},{"key":"7033_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13014-018-1031-0","volume":"13","author":"M Nakamura","year":"2018","unstructured":"Nakamura M, Hashimoto N, Mayahara H, Uezono H, Harada A, Nishikawa R, Matsuo Y, Kawaguchi H, Nishimura H. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence. Radiat Oncol. 2018;13:75.","journal-title":"Radiat Oncol"},{"key":"7033_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.radonc.2017.01.013","volume":"123","author":"RJ Klement","year":"2017","unstructured":"Klement RJ, Guckenberger M, Alheid H, Allgauer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease - influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123:227\u201333.","journal-title":"Radiother Oncol"},{"key":"7033_CR20","first-page":"395","volume":"16","author":"M Ito","year":"2018","unstructured":"Ito M, Kawamura T, Mori Y, Mori T, Takeuchi A, Oshima Y, Nakamura K, Aoyama T, Kaneda N, Ishiguchi T, Mizumatsu S. Dose distributions of high-precision radiotherapy treatment: a comparison between the CyberKnife and TrueBeam systems. Int J Radiat Res. 2018;16:395\u2013402.","journal-title":"Int J Radiat Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07033-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T19:20:01Z","timestamp":1623180001000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07033-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7033"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07033-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.15725\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.15725\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.15725\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"25 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving human participants were in accordance with the ethical standards of the institutional research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This retrospective observational study was approved by ethics committee, Aichi Medical University School of Medicine in Japan (application number 2018-H211). This study was also examined and approved by Aichi Cancer Center Hospital, Toyota Memorial Hospital, and Aoyama Hospital, Japan. The study was conducted in accordance with the tenets of the Declaration of Helsinki and its subsequent amendments. Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"540"}}